Search Within

Michael John Mauro

Formats
  1. Meeting Abstract (188)
  2. Journal Article (67)
  3. Review (8)
  4. Correspondence (4)
  5. Research Letter (3)
  6. Book Section (2)
  7. Editorial (2)
  8. Guidelines (2)
Groups
  1. Adult Leukemia (276)
  2. Center for Hematologic Malignancies (276)
  3. Department of Medicine (276)
  4. Hematologic Malignancies, Division of (276)
  5. Biostatistics Service (10)
  6. Epidemiology and Biostatistics (10)

More Groups

People
  1. Raajit Rampal (12)
  2. Ellin Berman (8)
  3. Eytan Stein (8)
  4. Martin Tallman (7)
  5. Amber King (6)
  6. Andriy Derkach (6)

More People

Years
  1. 2025 (7)
  2. 2024 (17)
  3. 2023 (26)
  4. 2022 (33)
  5. 2021 (21)
  6. 2020 (26)

More Years

Publications
  1. Blood (97)
  2. Clinical Lymphoma, Myeloma and Leukemia (44)
  3. Journal of Clinical Oncology (22)
  4. Haematologica (21)
  5. Leukemia (12)
  6. American Journal of Hematology (8)

More Publications

Publishers
  1. American Society of Hematology (101)
  2. Elsevier Inc. (47)
  3. American Society of Clinical Oncology (22)
  4. Ferrata Storti Foundation (21)
  5. Nature Publishing Group (13)
  6. John Wiley & Sons (8)

More Publishers

Results (276)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Imatinib discontinuation and Tki switching patterns in the retrospective and prospective cohorts in simplicity, a study of chronic-phase chronic myeloid leukemia (Cp-Cml) patients (Pts) in routine clinical practice
    Meeting Abstract

    Zyczynski, T.; Khoury, J.; Goldberg, S.; Mauro, M.; Michallet, M.; Paquette, R.; Foreman, A.; Subar, M.; Turner, M.; Daumont, M. M.; more...
    Value in Health (2016)

    Fulltext@MSK | Save
  • A chart review of lower dosing of ponatinib in patients with chronic myeloid leukemia (CML): Preliminary findings
    Meeting Abstract

    Mauro, M.; McGarry, L.; Inguilizian, A.; du Moulin, R.; Huang, H.
    Clinical Lymphoma, Myeloma and Leukemia (2016)

    Fulltext@MSK | Save
  • The PACE clinical trial vs the real-world: Comparison of ponatinib prescribing and duration of therapy in chronic-phase chronic myeloid leukemia (CP-CML) patients
    Meeting Abstract

    Mauro, M.; McGarry, L.; Yang, M.; Lustgarten, S.; Huang, H.
    Clinical Lymphoma, Myeloma and Leukemia (2016)

    Fulltext@MSK | Save
  • Rapid achievement of MR(4.5) after switching from imatinib to nilotinib in patients with chronic myeloid leukemia in chronic phase (CML-CP): Preliminary results from ENESTgoal
    Meeting Abstract

    Ritchie, E.; Deininger, M.; Erba, H.; Savona, M.; Paley, C.; Dautaj, I.; Mauro, M.
    Clinical Lymphoma, Myeloma and Leukemia (2016)

    Fulltext@MSK | Save
  • Ponatinib therapy for Philadelphia-positive ALL (Ph+ ALL) patients: Real-world clinical practice vs the PACE trial
    Meeting Abstract

    Mauro, M.; McGarry, L.; Yang, M.; Lustgarten, S.; Huang, H.
    Clinical Lymphoma, Myeloma and Leukemia (2016)

    Fulltext@MSK | Save
  • Acute myeloid leukemia masquerading as hepatocellular carcinoma
    Journal Article

    Abu-Zeinah, G. F.; Weisman, P.; Ganesh, K.; Katz, S. S.; Dogan, A.; Abou-Alfa, G. K.; Stein, E. M.; Jarnagin, W.; Mauro, M. J.; Harding, J. J.
    Journal of Gastrointestinal Oncology (2016)

    Fulltext@MSK | Save
  • Chronic myeloid leukemia: Is it dusk or dawn?
    Journal Article

    Mauro, M. J.
    Best Practice and Research: Clinical Haematology (2016)

    Fulltext@MSK | Save
  • Comparison of pace clinical trial vs real-world ponatinib prescribing and duration of therapy in chronic-phase chronic myeloid leukemia (CP-CML) patients
    Meeting Abstract

    Mauro, M.; McGarry, L. J.; Yang, M.; Lustgarten, S.; Huang, H.
    Haematologica (2016)

    Fulltext@MSK | Save
  • Preliminary findings from a chart review of lower dosing of ponatinib in chronic myeloid leukemia (CML) patients
    Meeting Abstract

    Mauro, M.; McGarry, L.; Inguilizian, A.; du Moulin, R.; Huang, H.
    Haematologica (2016)

    Fulltext@MSK | Save
  • Characteristics of ponatinib therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL) patients in real-world clinical practice compared to the pace trial
    Meeting Abstract

    Mauro, M.; McGarry, L. J.; Yang, M.; Lustgarten, S.; Huang, H.
    Haematologica (2016)

    Fulltext@MSK | Save